EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases
Methodological detailsEULAR points to consider, systematic literature review, expert consensus, multidisciplinary task force from eight European countries
- EULAR points to consider
- Systematic literature review
- Expert consensus
- Multidisciplinary task force from eight European countries
Recommendations
As issued by the authors
Proactive use of therapeutic drug monitoring (TDM) is in general not recommended
Reactive TDM could be considered in certain clinical situations
Original publication
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. Published 12 May 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →